Variant Bio Revenue and Competitors
Estimated Revenue & Valuation
- Variant Bio's estimated annual revenue is currently $9.1M per year.
- Variant Bio's estimated revenue per employee is $155,000
Employee Data
- Variant Bio has 59 Employees.
- Variant Bio grew their employee count by 4% last year.
Variant Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Computational Genetics | Reveal Email/Phone |
2 | VP, Head Partnerships | Reveal Email/Phone |
3 | VP Operations | Reveal Email/Phone |
4 | VP, Therapeutic Discovery | Reveal Email/Phone |
5 | Chief Operating Officer & Chief Legal Officer | Reveal Email/Phone |
6 | Chief Business Officer | Reveal Email/Phone |
7 | Director Finance | Reveal Email/Phone |
8 | Director Bioinformatics | Reveal Email/Phone |
9 | Assoc. Director HR | Reveal Email/Phone |
10 | Associate Director | Reveal Email/Phone |
Variant Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Variant Bio?
Variant Bio is developing therapies that will improve global health by studying the genes of people who are outliers for medically relevant traits.
keywords:N/A
N/A
Total Funding
59
Number of Employees
$9.1M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Variant Bio News
2022-04-17 - Nilit launches new bio-based Sensil variant
Nilit launches new bio-based Sensil variant ... widely used in the knitting sector, has launched a new variant of its premium Sensil brand.
2022-04-06 - HDT Bio Demonstrates RNA Vaccines Matched to SARS-CoV2 ...
In addition, the animal studies showed that even when not matched against variants, HDT Bio's RNA vaccine protects against lower respiratory...
2022-03-30 - HDT Bio Doses First Healthy Volunteer in US Phase 1 Trial of Next ...
The vaccine targets the Beta variant of SARS-CoV-2 and has a demonstrated ability to provide broad protection against multiple variants of the...
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 59 | -3% | N/A |
#2 | $14.3M | 59 | 11% | N/A |
#3 | $14.3M | 59 | 2% | N/A |
#4 | $7.7M | 59 | -5% | N/A |
#5 | $7.4M | 59 | -31% | N/A |